NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to supplying essential components for groundbreaking pharmaceutical research. Piroxicam-Beta-Cyclodextrin (CAS 96684-39-8) is one such critical intermediate, offering unique properties that facilitate advancements in drug formulation and therapeutic delivery.

Piroxicam-Beta-Cyclodextrin is a pharmaceutical formulation where the non-steroidal anti-inflammatory drug (NSAID) piroxicam is complexed with beta-cyclodextrin. This chemical marriage is not merely for combination but for functional enhancement. The primary goal is to overcome the inherent limitations of piroxicam, such as poor water solubility, which can impede its absorption and delay its onset of action. As a piroxicam beta cyclodextrin pharmaceutical intermediate, it provides a soluble and stable form of the drug.

The scientific advantages of this complex are significant. The piroxicam beta cyclodextrin benefits include improved absorption rates, leading to enhanced bioavailability. This means that a greater quantity of the drug enters the bloodstream, allowing it to reach target sites more effectively and produce its anti-inflammatory and analgesic effects faster. For researchers exploring NSAID complex for pain relief, this formulation offers a compelling solution for achieving rapid and sustained pain management.

Furthermore, the potential for reduced gastrointestinal side effects is a key area of interest. By modifying how piroxicam is released and absorbed, the complex may lessen the direct contact with the stomach lining, thus potentially reducing irritation and discomfort. This aspect highlights the importance of such advanced drug delivery systems in patient care.

For research institutions and pharmaceutical companies, acquiring Piroxicam-Beta-Cyclodextrin (CAS 96684-39-8) from a trusted supplier like NINGBO INNO PHARMCHEM CO.,LTD. is a strategic step. The opportunity to buy this intermediate allows for the exploration of its full potential in developing new and improved treatments for pain and inflammatory conditions, contributing to the broader field of pharmaceutical research and development.